Literature DB >> 24147485

Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.

Rajan Rakheja1, Hersh Chandarana, Linda DeMello, Kimberly Jackson, Christian Geppert, David Faul, Christopher Glielmi, Kent P Friedman.   

Abstract

OBJECTIVE: The purpose of this study was to assess the correlation between standardized uptake value (SUV) and apparent diffusion coefficient (ADC) of neoplastic lesions in the use of a simultaneous PET/MRI hybrid system. SUBJECTS AND METHODS: Twenty-four patients with known primary malignancies underwent FDG PET/CT. They then underwent whole-body PET/MRI. Diffusion-weighted imaging was performed with free breathing and a single-shot spin-echo echo-planar imaging sequence with b values of 0, 350, and 750 s/mm(2). Regions of interest were manually drawn along the contours of neoplastic lesions larger than 1 cm, which were clearly identified on PET and diffusion-weighted images. Maximum SUV (SUVmax) on PET/MRI and PET/CT images, mean SUV (SUVmean), minimum ADC (ADCmin), and mean ADC (ADCmean) were recorded on PET/MR images for each FDG-avid neoplastic soft-tissue lesion with a maximum of three lesions per patient. Pearson correlation coefficient was used to asses the following relations: SUVmax versus ADCmin on PET/MR and PET/CT images, SUVmean versus ADCmean, and ratio of SUVmax to mean liver SUV (SUV ratio) versus ADCmin. A subanalysis of patients with progressive disease versus partial treatment response was performed with the ratio of SUVmax to ADCmin for the most metabolically active lesion.
RESULTS: Sixty-nine neoplastic lesions (52 nonosseous lesions, 17 bone metastatic lesions) were evaluated. The mean SUVmax from PET/MRI was 7.0 ± 6.0; SUVmean, 5.6 ± 4.6; mean ADCmin, 1.10 ± 0.58; and mean ADCmean, 1.48 ± 0.72. A significant inverse Pearson correlation coefficient was found between PET/MRI SUVmax and ADCmin (r = -0.21, p = 0.04), between SUVmean and ADCmean (r = -0.18, p = 0.07), and between SUV ratio and ADCmin (r = -0.27, p = 0.01). A similar inverse Pearson correlation coefficient was found between the PET/CT SUVmax and ADCmin. Twenty of 24 patients had previously undergone PET/CT; five patients had a partial treatment response, and six had progressive disease according to Response Evaluation Criteria in Solid Tumors 1.1. The ratio between SUVmax and ADCmin was higher among patients with progressive disease than those with a partial treatment response.
CONCLUSION: Simultaneous PET/MRI is a promising technology for the detection of neoplastic disease. There are inverse correlations between SUVmax and ADCmin and between SUV ratio and ADCmin. Correlation coefficients between SUVmax and ADCmin from PET/MRI were similar to values obtained with SUVmax from the same-day PET/CT. Given that both SUV and ADC are related to malignancy and that the correlation between the two biomarkers is relatively weak, SUV and ADC values may offer complementary information to aid in determination of prognosis and treatment response. The combined tumoral biomarker, ratio between SUVmax and ADCmin, may be useful for assessing progressive disease versus partial treatment response.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24147485     DOI: 10.2214/AJR.13.11304

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  30 in total

Review 1.  Potential Role of PET/MRI for Imaging Metastatic Lymph Nodes in Head and Neck Cancer.

Authors:  Sungheon Gene Kim; Kent Friedman; Sohil Patel; Mari Hagiwara
Journal:  AJR Am J Roentgenol       Date:  2016-05-10       Impact factor: 3.959

Review 2.  The use of PET/MRI for imaging rectal cancer.

Authors:  Thomas A Hope; Zahra Kassam; Andreas Loening; Michelle M McNamara; Raj Paspulati
Journal:  Abdom Radiol (NY)       Date:  2019-11

3.  How PET/MR Can Add Value For Children With Cancer.

Authors:  Heike Daldrup-Link
Journal:  Curr Radiol Rep       Date:  2017-02-21

4.  Correlations between intravoxel incoherent motion diffusion-weighted MR imaging parameters and 18F-FDG PET/CT metabolic parameters in patients with vertebral bone metastases: initial experience.

Authors:  Sunghoon Park; Joon-Kee Yoon; Nam-Su Chung; Sang Hyun Kim; Jinwoo Hwang; Hyun Young Lee; Kyu-Sung Kwack
Journal:  Br J Radiol       Date:  2018-03-20       Impact factor: 3.039

Review 5.  PET/MRI: Where might it replace PET/CT?

Authors:  Eric C Ehman; Geoffrey B Johnson; Javier E Villanueva-Meyer; Soonmee Cha; Andrew Palmera Leynes; Peder Eric Zufall Larson; Thomas A Hope
Journal:  J Magn Reson Imaging       Date:  2017-03-30       Impact factor: 4.813

6.  Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT.

Authors:  Sarah Wulfert; Clemens Kratochwil; Peter L Choyke; Ali Afshar-Oromieh; Walter Mier; Hans-Ulrich Kauczor; Jens-Peter Schenk; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

Review 7.  Diffusion-weighted imaging of the liver: techniques and applications.

Authors:  Sara Lewis; Hadrien Dyvorne; Yong Cui; Bachir Taouli
Journal:  Magn Reson Imaging Clin N Am       Date:  2014-08       Impact factor: 2.266

8.  PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis.

Authors:  Bang-Bin Chen; Yu-Wen Tien; Ming-Chu Chang; Mei-Fang Cheng; Yu-Ting Chang; Chih-Horng Wu; Xin-Jia Chen; Ting-Chun Kuo; Shih-Hung Yang; I-Lun Shih; Hong-Shiee Lai; Tiffany Ting-Fang Shih
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-19       Impact factor: 9.236

9.  Simultaneous whole body (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with (18)F-fluorodeoxyglucose positron emission tomography computed tomography.

Authors:  Brian S Pugmire; Alexander R Guimaraes; Ruth Lim; Alison M Friedmann; Mary Huang; David Ebb; Howard Weinstein; Onofrio A Catalano; Umar Mahmood; Ciprian Catana; Michael S Gee
Journal:  World J Radiol       Date:  2016-03-28

Review 10.  Imaging for Response Assessment in Cancer Clinical Trials.

Authors:  Anna G Sorace; Asser A Elkassem; Samuel J Galgano; Suzanne E Lapi; Benjamin M Larimer; Savannah C Partridge; C Chad Quarles; Kirsten Reeves; Tiara S Napier; Patrick N Song; Thomas E Yankeelov; Stefanie Woodard; Andrew D Smith
Journal:  Semin Nucl Med       Date:  2020-06-10       Impact factor: 4.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.